Form 4 for MRNA Moderna
Accepted 2024-05-07 00:00:00 ET · period of report 2024-05-03 · accession 0001127602-24-014456 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-07 | 2024-05-03 | MRNA | NABEL ELIZABETH G | Dir | M - OptEx | — | +732 | 2,105 | +53% | — |
| DM | 2024-05-07 | 2024-05-06 | MRNA | NABEL ELIZABETH G | Dir | A - Grant | $0.00 | +6,647 | 5,668 | New | $0 |
| D | 2024-05-07 | 2024-05-03 | MRNA | NABEL ELIZABETH G | Dir | M - OptEx | $0.00 | -732 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-03 | M | A | 732 | — | 2,105 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 2 | Derivative | Restricted Stock Units | 2024-05-06 | A | A | 979 | $0.00 | 979 | D | — · — to — | 979 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F4) The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |
| 3 | Derivative | Restricted Stock Units | 2024-05-03 | M | D | 732 | $0.00 | 0 | D | — · — to — | 732 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F2) The shares subject to this restricted stock unit award vested in full on May 3, 2024. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-05-06 | A | A | 5,668 | $0.00 | 5,668 | D | $122.13 · — to 2034-05-06 | 5,668 Common Stock | (F3) This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |